For venture capitalists and pharmaceutical giants, the Antibody Drug Conjugate Market has become one of the most lucrative sectors for capital allocation. Recent years have seen a surge in multi-billion dollar licensing deals, as established firms race to replenish pipelines facing "patent cliffs."
This trend is most visible within the US Antibody Drug Conjugate Market, highlighted by Pfizer's...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt